You are here: Industry Insights > Therachon

News List

Pfizer successfully completes the acquisition of Therachon europeanpharmaceuticalreview
July 05, 2019
Pharmaceutical company, Pfizer, has announced it has completed the acquisition of Therachon for $340 million.
Pfizer Completes Acquisition of Therachon americanpharmaceuticalreview
July 03, 2019
Pfizer announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG.
Pfizer acquires Therachon to broaden its rare disease pipeline pharmaceutical-technology
May 23, 2019
Pfizer has entered into a definitive agreement to acquire all shares of Therachon, a private clinical-stage biotechnology company focused on rare diseases with pipeline assets in achondroplasia and short bowel syndrome therapies.
Pfizer to buy Therachon for $340 million upfront, gaining experimental drug for achondroplasia firstwordpharma
May 09, 2019
Pfizer said Wednesday that it entered into a definitive agreement to acquire all of the shares of Therachon for $340 million upfront, with a further $470 million in milestone payments linked to ...
Novo powers rare disease startup Therachon to $60M round fiercebiotech
August 10, 2018
Therachon has raised $60 million (€52 million) to take a phase 1 rare disease drug deeper into the clinic. The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.
Meyer leaves troubled uniQure for R&D post at Therachon fiercepharma
August 30, 2017
Meyer had been at the biotech for four years, but uniQure has been hit by commercial flops and major R&D shakeups
Catalent Biologics Collaborates with Therachon contractpharma
May 16, 2017
Will advance clinical development of innovative protein therapy for achondroplasia